OTCM
ERBKY
Market cap13bUSD
Sep 11, Last price
11.76USD
1D
-1.71%
1Q
-4.34%
IPO
33.01%
Name
Creso Pharma Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Creso Pharma Limited is a global pharmaceutical company focused on the development, registration, and commercialization of advanced cannabis and hemp-based solutions. These therapeutic products and nutraceuticals are designed for both human and animal health applications, with market presence spanning Europe, the Middle East, North America, and the Asia Pacific region. Beyond innovative product creation, the company also manages the cultivation, processing, and distribution of cannabis products, extending its reach to the retail sector. Its diverse portfolio includes specialized offerings such as anibidiol, a complementary nutritional supplement for companion animals. For human wellness, they provide cannaQIX, a nutraceutical blend of hemp oil extract, vitamins, and zinc, formulated to alleviate stress and bolster psychological and neurological functions. The company also manufactures topical and dermatological products, including cannaDOL, a CBD-infused gel combining cooling and warming essential oils. Established in 2015, Creso Pharma Limited maintains its headquarters in Nedlands, Australia.
Key people
Non-Executive Chairman of the Board · since 2017
David Russell
Chief Operating Officer · since 2017
Michal Masek
Co-Managing Directors - Hemp-Industries
Roman Strechaj
Co-Managing Directors - Hemp-Industries
Erlyn Dale
Joint Company Secretary · since 2018
Winton Willesee
Joint Company Secretary · since 2018
Adam Blumenthal
Non-Executive Director
James Anthony Ellingford
Non-Executive Director
Headquarters & legal address
L24, 300 Barangaroo Avenue
Barangaroo, NSW 2000
AU
Barangaroo, NSW 2000
AU
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT |